Lawson MacArtney is Director at Viking Therapeutics, Inc. (VKTX). They have made 5 open-market trades across 1 company since 2018, most recently 2026-01-02.
CIK 0001606831
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $501K since 2018, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| VKTX | 51,115 | $1.4M |
Shares reported on the most recent Form 4, priced at the 2026-01-05 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VKTX | SELL | 2024-11-08 | 2024-11-08 | $68.67 | $137K | -25.1% | -26.8% | -54.3% |
| VKTX | SELL | 2023-05-16 | 2023-05-18 | $24.00 | $384K | -5.7% | -6.3% | -39.0% |
| VKTX | SELL | 2023-04-24 | 2023-04-24 | $22.00 | $352K | -0.9% | +0.0% | -33.6% |
| VKTX | SELL | 2023-04-17 | 2023-04-18 | $20.00 | $416K | +5.6% | +14.9% | -23.3% |
| VKTX | BUY | 2018-05-29 | 2018-05-31 | $5.22 | $501K | -3.9% | -5.5% | +13.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.